The Beauty Health Company
NASDAQ:SKINHousehold & Personal Products
+$0.04 today
- Market cap
- $81.18M
- Beta
- 1.07
- P/E (TTM)
- -14.6
- EPS (TTM)
- -$0.05
Volume 0.05M
Average 0.95M
SKIN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
The Beauty Health CompanyNASDAQ: SKIN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $6.6M (cash outflow) fell 34.6% year over year, ahead of the -84.4% change in trailing-twelve-month net income. Sequentially, it fell 18.6% from the prior quarter.
Context
- Net income amounted to 3.2% of revenue in FY2025, down 5.5 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$15.01M (+58.0%) for the fiscal year ending Dec 2026, a step up from the -67.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.6M-18.6% QoQ
- Last fiscal yearDec 2025
- -$9.5M-67.4% YoY
- LTMMar 2026
- -$6.02M-84.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -34.6% | -116.5% | -81.9 pp |
| 1 year | -67.4% | +58.0% | +125.3 pp |
| 3-year CAGR | — | +6.1% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (9.5M) USD
- Year-over-year change
- +67.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.5M) | +67.4% |
| FY2024 | 2024-12-31 | (29.1M) | +70.9% |
| FY2023 | 2023-12-31 | (100.12M) | -325.6% |
| FY2022 | 2022-12-31 | 44.38M | +111.8% |
| FY2021 | 2021-12-31 | (375.11M) | — |
Net Income vs competitors
How SKIN compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -84.4% is the lowest of 7, against a peer median of -11.2%.
- Net income amounts to 2.0% of revenue for SKIN, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.19B USD | +101377.9% | +1397.2% | 5022.8% | |
| LTM Apr 2026 | $144.89M USD | +9.5% | +35.4% | 30.0% | |
| FY2025 | CN¥42.71M CNY | +181.5% | — | 2.3% | |
| LTM Mar 2026 | $7.06M USD | -69.2% | -33.6% | 4.2% | |
| LTM Mar 2026 | $6.03M USD | -31.8% | +12.6% | 6.6% | |
| LTM Mar 2026 | $6.02M USD | -84.4% | — | 2.0% | |
SLSNSolesence, Inc. Common Stock | LTM Mar 2026 | $944K USD | -72.4% | — | 1.6% |
| Peer median (excluding SKIN) | — | -11.2% | +24.0% | 5.4% | |
Competitors are the stored peer set for SKIN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (375.11M) | 44.38M | (100.12M) | (29.1M) | (9.5M) |
| Depreciation & Amortization | 21.14M | 22.02M | 34.68M | 33.68M | 25.35M |
| Deferred Income Tax | (3.76M) | (1.79M) | (1.08M) | (3.75M) | 2.22M |
| Stock-Based Compensation | 12.42M | 28.5M | 22.54M | 26.7M | 14.82M |
| Change in Working Capital | (18.66M) | (140.28M) | 23.36M | (27.39M) | 10.37M |
| Accounts Receivables | (31.01M) | (32.03M) | 12.85M | 20.8M | 8.59M |
| Inventory | (9.44M) | (82.1M) | 19.57M | (10.5M) | 15.8M |
| Accounts Payables | 10.52M | 1.61M | 15.78M | (43.78M) | (7.2M) |
| Other Working Capital | 11.27M | (27.77M) | (24.85M) | 6.08M | (6.83M) |
| Other Non-Cash Items | 335.62M | (59.43M) | 41.29M | 16M | 36.63M |
| Operating Cash Flow | (28.36M) | (106.6M) | 21.75M | 16.13M | 37.5M |
| Capital Expenditures | (15.62M) | (17.39M) | (13.05M) | (6.79M) | (303K) |
| Acquisitions (Net) | (22.9M) | (1.48M) | (18.46M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 781K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (37.73M) | (18.87M) | (31.51M) | (6.79M) | (5.16M) |
| Debt Repayment | 524.51M | 0 | 0 | (156.08M) | (173.35M) |
| Common Stock Issued | 938.38M | 0 | 0 | 0 | (1.57M) |
| Common Stock Repurchased | 0 | (160M) | (32.4M) | (1.96M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (503.86M) | (45.24M) | (1.82M) | (302K) | 26K |
| Financing Cash Flow | 959.04M | (205.24M) | (37.45M) | (158.34M) | (174.9M) |
| Effect of Forex Changes | (543K) | (2.98M) | 2.03M | (3.96M) | 5.21M |
| Net Change in Cash | 892.4M | (333.69M) | (45.17M) | (152.96M) | (137.4M) |
| Free Cash Flow | (43.98M) | (123.99M) | 8.7M | 9.34M | 37.18M |
The Beauty Health Company
NASDAQ:SKIN
Intrinsic Alpha fair value
Locked
Current Price
$12.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.